S
Salvatore Siena
Researcher at University of Milan
Publications - 572
Citations - 62791
Salvatore Siena is an academic researcher from University of Milan. The author has contributed to research in topics: Colorectal cancer & Panitumumab. The author has an hindex of 91, co-authored 524 publications receiving 53868 citations. Previous affiliations of Salvatore Siena include Novartis & Indiana University.
Papers
More filters
Journal ArticleDOI
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
Rafal Dziadziuszko,Matthew G Krebs,Filippo de Braud,Salvatore Siena,Alexander Drilon,Robert C. Doebele,Manish R. Patel,Byoung Chul Cho,Stephen V. Liu,Myung-Ju Ahn,Chao Hua Chiu,Anna F. Farago,Chia-Chi Lin,Christos S. Karapetis,Yu Chung Li,Bann Mo Day,David Chen,Timothy R. Wilson,Fabrice Barlesi,Fabrice Barlesi +19 more
TL;DR: In this article, the authors reported the results of an updated integrated integrated study of the tyrosine receptor kinase ROS proto-oncogene 1 (ROS1) in non-small-cell lung cancer (NSCLC).
Journal ArticleDOI
Synthesis and characterization of an antihuman T-lymphocyte saporin immunotoxin (OKT1-SAP) with in vivo stability into nonhuman primates.
Salvatore Siena,Douglas A. Lappi,M. Bregni,A Formosa,Villa S,M Soria,Gianni Bonadonna,A.M. Gianni +7 more
TL;DR: The findings presented in this article indicate the feasibility of using OKT1-SAP as a therapeutic tool and provide information that will facilitate the rational use of immunotoxins as a treatment modality in humans.
Journal ArticleDOI
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
Laurence Gladieff,Annamaria Ferrero,G. De Rauglaudre,Chris Brown,Paul Vasey,Alexander Reinthaller,Eric Pujade-Lauraine,N. Reed,Domenica Lorusso,Salvatore Siena,H. Helland,Laurie Elit,Sven Mahner +12 more
TL;DR: Carboplatin-PLD has a more favorable risk-benefit profile than CP in patients with partially platinum-sensitive ROC and should be considered an effective treatment option for these patients, according to the CALYPSO trial.
Journal ArticleDOI
Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.
Andrea Sartore-Bianchi,Filippo Pietrantonio,Sara Lonardi,Benedetta Mussolin,Francesco Rua,Elisabetta Fenocchio,Alessio Amatu,Salvatore Corallo,Chiara Manai,Federica Tosi,Paolo Manca,Francesca Daniel,Valter Torri,Angelo Vanzulli,Giovanni Cappello,Caterina Marchiò,Anna Sapino,Silvia Marsoni,Salvatore Siena,Alberto Bardelli +19 more
TL;DR: This data indicates that within RAS status therapeutic actionability remains confined to the limited subgroups of ERBB2 amphetamine-like substances in metastatic colorectal cancer.
Journal ArticleDOI
Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.
A. M. Gianni,M. Bregni,Salvatore Siena,Michele Magni,M Di Nicola,F. Lombardi,Corrado Tarella,Alessandro Pileri,Gianni Bonadonna +8 more
TL;DR: The use of rhGM- CSF or rhG-CSF makes high-dose etoposide a safe outpatient regimen and should encourage the inclusion of this highly effective and well-tolerated drug in novel treatment strategies that use high- dose therapy early in the clinical course of chemosensitive tumors.